ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Metrics to compare | PROK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROKPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −2.4x | −0.5x | |
PEG Ratio | 0.31 | 0.01 | 0.00 | |
Price/Book | −0.2x | 2.1x | 2.6x | |
Price / LTM Sales | 580.2x | 4.2x | 3.0x | |
Upside (Analyst Target) | - | 180.7% | 49.2% | |
Fair Value Upside | Unlock | 4.1% | 7.4% | Unlock |